Login to Your Account

Daiichi declines to carry Charleston pain program forward

By Michael Fitzhugh
Staff Writer

Thursday, August 31, 2017

Just weeks ahead of the planned resubmission of the FDA new drug application for a pain pill tailored to reduce OINV, one-time backer Daiichi Sankyo Co. Ltd. is handing rights to the drug back to Charleston Laboratories Inc. and booking a $252.7 million loss on the project.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription